What is MBX Biosciences, Inc.'s depreciation?

MBX Biosciences, Inc. (MBX) reported depreciation of $64K in Q1 2026.

How has MBX Biosciences, Inc.'s depreciation changed year-over-year?

MBX Biosciences, Inc.'s depreciation decreased by 16.9% year-over-year, from $77K to $64K.

Amylyx Pharmaceuticals, Inc.AMLX

——

Cogent Biosciences, Inc.COGT

——

BioCryst PharmaceuticalsBCRX

——

Operating income-$27.3M-2.8%

Net income-$23.5M+1.5%

EPS (diluted)-$0.50+29.6%

Cash & equivalents$45.2M+51.2%

Total debt$555.0K+327%

Total equity$437.8M+85.9%

Total assets$452.7M+84.1%

Operating cash flow-$20.2M+10.9%

CapEx$437.0K+1,357%

Free cash flow-$20.6M+9.1%

Market cap$2.3B+475%

Enterprise value$2.26B+533%

Return on equity-25.7%—

Debt / equity0×0.0×

Current ratio30.8×+7.5×

Reported directly by MBX Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is MBX Biosciences, Inc.'s depreciation?: MBX Biosciences, Inc. (MBX) reported depreciation of $64K in Q1 2026.
How has MBX Biosciences, Inc.'s depreciation changed year-over-year?: MBX Biosciences, Inc.'s depreciation decreased by 16.9% year-over-year, from $77K to $64K.